Payment overview · 2025
General Payments
$1,313.62
53 reported records · 15 companies
Healthcare provider profile · identity verified
Rodolfo Baguinguito Protacio, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GLENDALE, CA · NPI 1154320836
Verified facts
What the public records show
CMS Open Payments records show Rodolfo Baguinguito Protacio, M.D. received $1,313.62 in general payments during 2025 across 53 reported records.
Novo Nordisk Inc accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Kerendia, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $285.33 | 21.7% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $164.34 | 12.5% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $136.64 | 10.4% | 6 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $127.99 | 9.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $121.52 | 9.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $92.53 | 7.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.28 | 4.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $61.91 | 4.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $50.03 | 3.8% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $47.53 | 3.6% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $44.63 | 3.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.11 | 3.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.80 | 2.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.75 | 1.7% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.23 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,313.62 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $215.05 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $136.64 | 6 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $127.99 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $92.53 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $75.96 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $68.10 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $68.10 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $64.69 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $61.91 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $50.03 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $47.53 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $45.56 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $45.56 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.32 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $44.63 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.11 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $34.98 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.80 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.55 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.30 | 1 | 2025 |
Source payment records
|
|||||
| NEXIUM Normalized: nexium |
Drug | AstraZeneca Pharmaceuticals LP | $21.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 41 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 211 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 54 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 131 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
28 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
94 | 29 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
211 | 66 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
211 | 66 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
131 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
59 | 21 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 903 | 252 |
| Amlodipine Besylate | Amlodipine Besylate | 822 | 229 |
| Losartan Potassium | Losartan Potassium | 703 | 200 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 674 | 202 |
| Metformin Hcl | Metformin Hcl | 635 | 172 |
| Levothyroxine Sodium | Levothyroxine Sodium | 467 | 116 |
| Gabapentin | Gabapentin | 282 | 96 |
| Carvedilol | Carvedilol | 280 | 73 |
| Alendronate Sodium | Alendronate Sodium | 252 | 76 |
| Omeprazole | Omeprazole | 212 | 76 |
| Jardiance | Empagliflozin | 211 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 210 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 61 |
| Atenolol | Atenolol | 198 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 55 |
| Lisinopril | Lisinopril | 197 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 188 | 57 |
| Fenofibrate | Fenofibrate | 186 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 52 |
| Simvastatin | Simvastatin | 162 | 46 |
| Allopurinol | Allopurinol | 151 | 51 |
| Hydralazine Hcl | Hydralazine Hcl | 145 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 37 |
| Glimepiride | Glimepiride | 137 | 33 |
| Benazepril Hcl | Benazepril Hcl | 134 | 35 |
| Famotidine | Famotidine | 132 | 46 |
| Ozempic | Semaglutide | 131 | 21 |
| Eliquis | Apixaban | 130 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 115 | 34 |
| Azithromycin | Azithromycin | 114 | 87 |
| Furosemide | Furosemide | 114 | 36 |
| Montelukast Sodium | Montelukast Sodium | 111 | 40 |
| Farxiga | Dapagliflozin Propanediol | 94 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 87 | 33 |
| Finasteride | Finasteride | 86 | 24 |
| Glipizide | Glipizide | 80 | 23 |
| Januvia | Sitagliptin Phosphate | 76 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 29 |
| Latanoprost | Latanoprost | 68 | 24 |
| Meclizine Hcl | Meclizine Hcl | 67 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 18 |
| Enalapril Maleate | Enalapril Maleate | 65 | 13 |
| Ibuprofen | Ibuprofen | 65 | 30 |
| Ezetimibe | Ezetimibe | 61 | 18 |
| Lovastatin | Lovastatin | 61 | 17 |
| Spironolactone | Spironolactone | 61 | 17 |
| Tradjenta | Linagliptin | 61 | 14 |
| Meloxicam | Meloxicam | 60 | 19 |
| Rybelsus | Semaglutide | 59 | 21 |
| Mometasone Furoate | Mometasone Furoate | 58 | 25 |
| Nifedipine Er | Nifedipine | 58 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 56 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 22 |
| Kerendia | Finerenone | 54 | 14 |
| Irbesartan | Irbesartan | 53 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 52 | 22 |
| Memantine Hcl | Memantine Hcl | 52 | 17 |
| Clonidine Hcl | Clonidine Hcl | 51 | 19 |
| Mirtazapine | Mirtazapine | 51 | 21 |
| Sertraline Hcl | Sertraline Hcl | 45 | 16 |
| Nitroglycerin | Nitroglycerin | 44 | 17 |
| Potassium Chloride | Potassium Chloride | 44 | 13 |
| Gemtesa | Vibegron | 41 | 11 |
| Donepezil Hcl | Donepezil Hcl | 40 | 16 |
| Colchicine | Colchicine | 39 | 22 |
| Vascepa | Icosapent Ethyl | 37 | suppressed |
| Fluocinonide | Fluocinonide | 36 | 13 |
| Celecoxib | Celecoxib | 35 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Timolol Maleate | Timolol Maleate | 33 | suppressed |
| Prednisone | Prednisone | 32 | 22 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Telmisartan | Telmisartan | 31 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | 17 |
| Hydrocortisone | Hydrocortisone | 29 | 12 |
| Linzess | Linaclotide | 29 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | 15 |
| Febuxostat | Febuxostat | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Prolia | Denosumab | 28 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 15 |
| Lumigan | Bimatoprost | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 13 |
| Methimazole | Methimazole | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 16 |
| Restasis | Cyclosporine | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 16 | 12 |
| Pregabalin | Pregabalin | 16 | suppressed |
| Travoprost | Travoprost | 16 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Folic Acid | Folic Acid | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Bystolic | Nebivolol Hcl | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,313.62 · 53 records | Novo Nordisk Inc | ACCRUFER, AFREZZA, AREXVY, CREON, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, JARDIANCE, KRYSTEXXA, Kerendia, NEXIUM, OTEZLA, Ozempic, REPATHA, SHINGRIX, TRELEGY ELLIPTA, VRAYLAR, Wegovy, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error